Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Neuroprotection in Acute Ischemic Stroke
NCT03223220Phase 3Not yet recruiting
- Sponsor
- Lower Merion Neurology Research Foundation
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketamine in ischemic stroke (2 arms), sponsored by Lower Merion Neurology Research Foundation. Primary endpoint: Change in Weighted Modified Rankin Scale Score at Day 90. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03223220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03223220.